Investigation of magnetization transfer ratio-derived pial and subpial abnormalities in the multiple sclerosis spinal cord

Brain

Volumn 137, Issue 9, 2014, Pages 2456-2468

  Kearney, Hugh ^a   Yiannakas, Marios C ^a   Samson, Rebecca S ^a   Wheeler Kingshott, Claudia A M ^a,b   Ciccarelli, Olga ^a,b   Miller, David H ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Magnetization transfer ratio; MRI; MTR; Multiple sclerosis; Spinal cord

Indexed keywords

ADULT; ARTICLE; BRAIN REGION; CERVICAL SPINAL CORD; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE COURSE; FEMALE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MAGNETIZATION TRANSFER RATIO; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PIA MATER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; REMISSION; SPINAL CORD ATROPHY; WHITE MATTER;

MAGNETIZATION TRANSFER RATIO; MRI; MTR; MULTIPLE SCLEROSIS; SPINAL CORD;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PIA MATER; SPINAL CORD;

EID: 84906687539     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu171     Document Type: Article

References (75)

1. Agosta F, Pagani E, Caputo D, Filippi M. Associations between cervical cord gray matter damage and disability in patients with multiple sclerosis. Arch Neurol 2007; 64: 1302-5.
2. Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, Nataf S. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 2010; 68: 465-76.
3. Audoin B, Au Duong MV, Ranjeva JP, Ibarrola D, Malikova I, Confort- Gouny S, et al. Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosis. Hum Brain Mapp 2005; 24: 216-28.
4. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256-66.
5. Bender R, Lange S. Adjusting for multiple testing: when and how? J Clin Epidemiol 2001; 54: 343-349.
6. Brown DA, Sawchenko PE. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J Comp Neurol 2007; 502: 236-60.
7. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 1962; 25: 315-20.
8. BöL, Geurts JJ, van der Valk P, Polman C, Barkhof F. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol 2007; 64: 76-80.
9. Bø L, Vedeler CA, Nyland HI, Trapp BD, Mørk SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003; 62: 723-32.
10. Charil A, Caputo D, Cavarretta R, Sormani MP, Ferrante P, Filippi M. Cervical cord magnetization transfer ratio and clinical changes over 18 months in patients with relapsing-remitting multiple sclerosis: a preliminary study. Mult Scler 2006; 12: 662-5.
11. Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007; 64: 1416-22.
12. Chard DT, Jackson JS, Miller DH, Wheeler-Kingshott CA. Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging 2010; 32: 223-8.
13. Chen JT, Easley K, Schneider C, Nakamura K, Kidd GJ, Chang A, et al. Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology 2013; 80: 246-52.
14. Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012; 135: 2925-37.
15. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 2006; 108: 327-32.
16. Cook LL, Foster PJ, Mitchell JR, Karlik SJ. In vivo 4.0-T magnetic resonance investigation of spinal cord inflammation, demyelination, and axonal damage in chronic-progressive experimental allergic encephalomyelitis. J Magn Reson Imaging 2004; 20: 563-71.
17. Dawson JW. The histology of multiple sclerosis. Trans R Soc Edinburgh 1916; 50: 517-740.
18. DeLuca GC, Alterman R, Martin JL, Mittal A, Blundell S, Bird S, et al. Casting a light on multiple sclerosis heterogeneity: the role of HLADRB1 on spinal cord pathology. Brain 2013; 136: 1025-34.
19. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004; 127: 1009-18.
20. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006; 129: 1507-16.
21. Dietrich O, Reiser MF, Schoenberg SO. Artifacts in 3-Tesla MRI: physical background and reduction strategies. Eur J Radiol 2008; 65: 29-35.
22. Dousset V, Grossman RI, Ramer KN, Schnall MD, Young LH, Gonzalez- Scarano F, et al. Experimental allergic encephalomyelitis and multiple sclerosis:lesion characterization with magnetization transfer imaging. Radiology 1992; 182: 483-91.
23. Evangelou N, DeLuca GC, Owens T, Esiri MM. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain 2005; 128: 29-34.
24. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47: 391-95.
25. Fernando KT, Tozer DJ, Miszkiel KA, Gordon RM, Swanton JK, Dalton CM, Barker GJ, Plant GT, Thompson AJ, Miller DH. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2005; 128: 2911-25.
26. Fischer J, Rudick RA, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS society clinical outcomes assessment task force. Mult Scler 1999; 5: 244-50.
27. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-17.
28. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-89.
29. Ganter P, Prince C, Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 1999; 25: 459-67.
30. Geurts JJ, BöL, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 2005; 26: 572-7.
31. Healy BC, Arora A, Hayden MA, Ceccarelli A, Tauhid SS, Neema M, et al. Approaches to normalization of spinal cord volume: application to multiple sclerosis. J Neuroimaging 2012; 22: 12-9.
32. Horsfield MA, Sala S, Neema M, Absinta M, Bakshi A, Sormani MP, et al. Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage 2010; 50: 446-55.
33. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011; 134: 2755-71.
34. Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult. Scler 2002; 8: 532-3.
35. Kearney H, Yiannakas MC, Abdel-Aziz K, Wheeler-Kingshott CA, Altmann DR, Ciccarelli O, et al. Improved MRI quantification of spinal cord atrophy in multiple sclerosis. J Magn Reson Imaging 2014; 39: 617-23.
36. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201: 195-200.
37. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
38. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-12.
39. Laurent D, Wasvary J, Yin J, Rudin M, Pellas TC, O'Byrne E. Quantitative and qualitative assessment of articular cartilage in the goat knee with magnetization transfer imaging. Magn Reson Imaging 2001; 19: 1279-86.
40. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon b-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44-51.
41. Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon b-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry 2003; 74: 1090-4.
42. Lovas G, Szilágyi N, Majtényi K, Palkovits M, Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000; 123: 308-17.
43. Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011; 134: 534-41.
44. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 1996; 46: 907-911.
45. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365: 2188-97.
46. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68: 477-93.
47. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicle in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130: 1089-104.
48. Maynard FM Jr, Bracken MB, Creasey G, Ditunno JF Jr, Donovan WH, Ducker TB, et al. International standards for neurological and functional classification of spinal cord injury. american spinal injury association. Spinal Cord 1997; 35: 266-74.
49. McGavern DB, Murray PD, Rivera-Quiñones C, Schmelzer JD, Low PA, Rodriguez M. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 2000; 123: 519-31.
50. Meinl E, Krumbholz M, Derfuss T, Junker A, Hohlfeld R. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci 2008; 274: 42-4.
51. Mezzapesa DM, Rocca MA, Falini A, Rodegher ME, Ghezzi A, Comi G, Filippi M. A preliminary diffusion tensor and magnetization transfer magnetic resonance imaging study of early-onset multiple sclerosis. Arch Neurol 2004; 61: 366-8.
52. Millen JW, Woollam DH. On the nature of the pia mater. Brain 1961; 84: 514-20.
53. Moll NM, Cossoy MB, Fisher E, Staugaitis SM, Tucky BH, Rietsch AM, et al. Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 2009; 66: 44-53.
54. Montalban X, Sastre-Garriga J, TintoréM, Brieva L, Aymerich FX, Río J, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 2009; 15: 1195-205.
55. Mouritzen Dam A. Shrinkage of the brain during histological procedures with fixation in formaldehyde solutions of different concentrations. J Hirnforsch 1979; 20: 115-19.
56. Oh J, Zackowski K, Chen M, Newsome S, Saidha S, Smith SA, et al. Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis. Mult Scler 2013; 19: 427-35.
57. Oppenheimer DR. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 1978; 4: 151-62.
58. Peterson JW, BöL, Mörk S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389-400.
59. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
60. Ransohoff RM. Immunology: in the beginning. Nature 2009; 492: 41-2.
61. Reina MA, De León Casasola Ode L, Villanueva MC, López A, Machés F, De Andrés JA. Ultrastructural findings in human spinal pia mater in relation to subarachnoid anesthesia. Anesth Analg 2004; 98: 1479-85.
62. Samson RS, Cardoso MJ, Muhlert N, Sethi V, Wheeler-Kingshott CA, Ron M, et al. Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups. Mult Scler 2014 [Epub ahead of print] PMID: 24552746.
63. Schirmer L, Antel JP, Brück W, Stadelmann C. Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis. Brain Pathol 2011; 21: 428-40.
64. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004; 56: 407-15.
65. Schmierer K, Parkes HG, So PW, An SF, Brandner S, Ordidge RJ, et al. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain 2010; 133: 858-67.
66. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164-74.
67. Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, et al. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 2013; 80: 69-75.
68. Stroman PW, Wheeler-Kingshott C, Bacon M, Schwab JM, Bosma R, Brooks J, et al. The current state-of-the-art of spinal cord imaging: methods. Neuroimage 2014; 84: 1070-81.
69. Tench CR, Morgan PS, Constantinescu CS. Measurement of cervical spinal cord cross-sectional area by MRI using edge detection and partial volume correction. J Magn Reson Imaging 2005; 21: 197-203.
70. Udupa JK, Samarasekera S. Fuzzy connectedness and object definition: theory, algorithms and applications in image segmentation. Graph Models Image Process 1996; 58: 246-61.
71. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006; 67: 960-7.
72. Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005; 64: 1101-7.
73. Yiannakas MC, Kearney H, Samson RS, Chard DT, Ciccarelli O, Miller DH, et al. Feasibility of grey matter and white matter segmentation of the upper cervical cord in vivo: a pilot study with application to magnetisation transfer measurements. Neuroimage 2012; 63: 1054-9.
74. Zackowski KM, Smith SA, Reich DS, Gordon-Lipkin E, Chodkowski BA, Sambandan DR, et al. Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 2009; 132: 1200-9.
75. Zhao W, Cohen-Adad J, Polimeni JR, Keil B, Guerin B, Setsompop K, Serano P, Mareyam A, Hoecht P, Wald LL. Nineteen-channel receive array and four-channel transmit array coil for cervical spinal cord imaging at 7T. Magn Reson Med 2013, Advance Access published on August 20, doi: 10.1002/mrm.24911 [Epub ahead of print].